GlassScriptPhysician profile
Kerry Preston
NPI 1588649537
$2,385.41
in general payments reported to CMS, 2019-2025
23 companies · $465 in 2025
The $465 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $168 · 2021: $471 · 2022: $356 · 2023: $381 · 2024: $241 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $471.75 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $321.07 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $226.05 | 2022-2023 | Acuvue |
| Abbvie INC. | $203.40 | 2022-2025 | |
| Alcon Vision LLC | $186.41 | 2019-2023 | Clareon |
| Aerie Pharmaceuticals, INC. | $138.18 | 2020-2021 | |
| Sight Sciences, INC. | $107.94 | 2021-2025 | Omni Surgical System |
| Optos, INC. | $92.73 | 2021 | |
| Glaukos Corporation | $81.87 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $78.05 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $67.92 | 2019 | |
| Dompe US, INC. | $66.88 | 2025 | Oxervate |
| Rxsight INC | $63.40 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Contact Lens |
| Amgen INC. | $60.44 | 2025 | Tepezza |
| Allergan, INC. | $54.79 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $37.28 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $34.26 | 2019-2021 | |
| Ocular Therapeutix, INC. | $20.98 | 2025 | Dextenza |
| Rayner Intraocular Lenses Limited | $15.93 | 2025 | Rayone Aspheric, Rayner Cataract Set 1, Rayone Emv |
| Horizon Therapeutics Plc | $15.41 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $14.33 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.75 | 2023 | Flarex |
| Maculogix, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.